{
  "id": 19390971,
  "title": "Jade Biosciences at Guggenheim conference: cash-rich push into autoimmune drugs",
  "url": "https://urgent.news/2026/11/10/jade-biosciences-at-guggenheim-conference-cash-rich-push-into",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-10T20:34:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/jade-biosciences-at-guggenheim-conference-cashrich-push-into-autoimmune-drugs-93CH-5016713"
  },
  "original_language": "en",
  "account": "On 10 November 2026, Jade Biosciences (JBIO) addressed an autoimmune strategy in its presentation at the 3rd Annual Guggenheim Healthcare Innovation Conference. The company highlighted three ongoing monoclonal antibody programs, saying its $461 million cash balance can fund development until late 2028.\n\nCEO focus remained on its lead IgA nephropathy asset, JADE101, an anti-APRIL monoclonal antibody designed with femtomolar binding affinity to APRIL. The drug uses a YTE modification in the Fc region to extend half-life and is proposed for quarterly dosing. Phase II, which began in May 2024, is expected to yield interim data in the second quarter of 2027. Phase III, starting in the fourth quarter of 2024, will be global with 2:1 randomization in favor of active drug. Interim data from Phase II are anticipated in the second quarter of 2027.\n\nJade also introduced JADE201, an afucosylated anti-BAFF-R monoclonal antibody aimed at rheumatoid arthritis, and JADE301, a dermatomyositis program based on Pfizer's dazukibart, targeting interferon beta. Both are at earlier stages, with first data expected in 2027. The company emphasized that its balance sheet remains robust enough to support simultaneous development of multiple programs.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}